Fungal infections of the respiratory tract

Clinical Mycology with CD-ROM

Volumn , Issue , 2009, Pages 561-589

  Donoghue, Martha ^a   Seibel, Nita L ^a   Francis, Peter S ^b   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Hematology/Oncology PC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864558765     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5680-5/00027-X     Document Type: Chapter

References (391)

1. Latge J.P. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999, 12. 310-50.
2. Cockrill B.A., Hales C.A. Allergic bronchopulmonary aspergillosis. Annu Rev Med 1999, 50. 303-16.
3. Hartwick R.W., Batsakis J.G. Sinus aspergillosis and allergic fungal sinusitis. Ann Otol Rhinol Laryngol 1991, 100. 427-30.
4. Kurup V.P., Grunig G., Knutsen A.P., et al. Cytokines in allergic bronchopulmonary aspergillosis. Res Immunol 1998, 149. 466-77 discussion 515-16.
5. Miller W.T. Aspergillosis: a disease with many faces. Semin Roentgenol 1996, 31:52-66.
6. Zhaoming W., Lockey R.F. A review of allergic bronchopulmonary aspergillosis. J Investig Allergol Clin Immunol 1996, 6. 144-51.
7. Gefter W.B. The spectrum of pulmonary aspergillosis. J Thorac Imag 1993, 7:56-74.
8. Denning D.W. Invasive aspergillosis. Clin Infect Dis 1998, 26:781-803. quiz 804-5.
9. Denning D.W., Stevens D.A. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990, 12. 1147-201.
10. Pannuti C., Gingrich R., Pfaller M.A., et al. Nosocomial pneumonia in patients having bone marrow transplant. Attributable mortality and risk factors. Cancer 1992, 69. 2653-62.
11. Pannuti C.S., Gingrich R.D., Pfaller M.A., et al. Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: a 9-year study. J Clin Oncol 1991, 9:77-84.
12. Walsh T.J., Dixon D.M. Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment. Eur J Epidemiol 1989, 5. 131-42.
13. Agarwal R., Gupta D., Aggarwal A.N., et al. Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending a chest clinic in north India. Chest 2006, 130. 442-8.
14. Denning D.W., O'Driscoll B.R., Hogaboam C.M., et al. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 2006, 27. 615-26.
15. O'Driscoll B.R., Hopkinson L.C., Denning D.W. Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions. BMC Pulm Med 2005, 5:4.
16. Netea M.G., Van der Graaf C., Van der Meer J.W., et al. Recognition of fungal pathogens by Toll-like receptors. Eur J Clin Microbiol Infect Dis 2004, 23. 672-6.
17. Redecke V., Hacker H., Datta S.K., et al. Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J Immunol 2004, 172. 2739-43.
18. Hope W.W., Walsh T.J., Denning D.W. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005, 43(suppl 1). S207-38.
19. Procop G.W., Johnston W.W. Diagnostic value of conidia associated with pulmonary oxalosis: evidence of an Aspergillus niger infection. Diagn Cytopathol 1997, 17. 292-4.
20. Gerson S.L., Talbot G.H., Hurwitz S., et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984, 100. 345-51.
21. Walsh T.J. Invasive pulmonary aspergillosis in patients with neoplastic diseases. Semin Respir Infect 1990, 5. 111-22.
22. Walsh T.J., Mendelsohn G. Invasive aspergillosis complicating Cushing's syndrome. Arch Intern Med 1981, 141. 1227-8.
23. Conesa D., Rello J., Valles J., et al. Invasive aspergillosis: a life-threatening complication of short-term steroid treatment. Ann Pharmacother 1995, 29. 1235-7.
24. Monlun E., de Blay F., Berton C., et al. Invasive pulmonary aspergillosis with cerebromeningeal involvement after short-term intravenous corticosteroid therapy in a patient with asthma. Respir Med 1997, 91. 435-7.
25. Ng T.T., Robson G.D., Denning D.W. Hydrocortisone-enhanced growth of Aspergillus spp.:implications for pathogenesis. Microbiology 1994, 140(Pt 9). 2475-9.
26. Cornillet A., Camus C., Nimubona S., et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006, 43. 577-84.
27. Kemper C.A., Hostetler J.S., Follansbee S.E., et al. Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS. Clin Infect Dis 1993, 17. 344-52.
28. Roilides E., Holmes A., Blake C., et al. Impairment of neutrophil antifungal activity against hyphae of Aspergillus fumigatus in children infected with human immunodeficiency virus. J Infect Dis 1993, 167. 905-11.
29. Roilides E., Holmes A., Blake C., et al. Defective antifungal activity of monocyte-derived macrophages from human immunodeficiency virus-infected children against Aspergillus fumigatus. J Infect Dis 1993, 168. 1562-5.
30. Keating J.J., Rogers T., Petrou M., et al. Management of pulmonary aspergillosis in AIDS: an emerging clinical problem. J Clin Pathol 1994, 47. 805-9.
31. Miller W.T., Sais G.J., Frank I., et al. Pulmonary aspergillosis in patients with AIDS. Clinical and radiographic correlations. Chest 1994, 105:37-44.
32. Commers J.R., Robichaud K.J., Pizzo P.A. New pulmonary infiltrates in granulocytopenic cancer patients being treated with antibiotics. Pediatr Infect Dis 1984, 3. 423-8.
33. Burch P.A., Karp J.E., Merz W.G., et al. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol 1987, 5. 1985-93.
34. Albelda S.M., Talbot G.H., Gerson S.L., et al. Role of fiberoptic bronchoscopy in the diagnosis of invasive pulmonary aspergillosis in patients with acute leukemia. Am J Med 1984, 76. 1027-34.
35. Panos R.J., Barr L.F., Walsh T.J., et al. Factors associated with fatal hemoptysis in cancer patients. Chest 1988, 94. 1008-13.
36. Katz J.F., Yassa N.A., Bhan I., et al. Invasive aspergillosis involving the thoracic aorta: CT appearance. Am J Roentgenol 1994, 163. 817-9.
37. Hayashi H., Takagi R., Onda M., et al. Invasive pulmonary aspergillosis occluding the descending aorta and left pulmonary artery: CT features. J Comput Assist Tomogr 1994, 18. 492-4.
38. Saliou C., Badia P., Duteille F., et al. Mycotic aneurysm of the left subclavian artery presented with hemoptysis in an immunosuppressed man: case report and review of literature. J Vasc Surg 1995, 21:697-702.
39. Venuta F., Rendina E.A., Pescarmona E., et al. Salvage lung resection for massive hemoptysis after resolution of pulmonary aspergillosis in a patient with acute leukemia. Scand Cardiovasc J 1997, 31. 51-3.
40. Walsh T.J., Bulkley B.H. Aspergillus pericarditis: clinical and pathologic features in the immunocompromised patient. Cancer 1982, 49:48-54.
41. Gross B.H., Spitz H.B., Felson B. The mural nodule in cavitary opportunistic pulmonary aspergillosis. Radiology 1982, 143. 619-22.
42. Orr D.P., Myerowitz R.L., Dubois P.J. Patho-radiologic correlation of invasive pulmonary aspergillosis in the compromised host. Cancer 1978, 41. 2028-39.
43. Slevin M.L., Knowles G.K., Phillips M.J., et al. The air crescent sign of invasive pulmonary aspergillosis in acute leukaemia. Thorax 1982, 37. 554-5.
44. Hauggaard A., Ellis M., Ekelund L. Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis. Acta Radiol 2002, 43. 292-8.
45. Kuhlman J.E., Fishman E.K., Burch P.A., et al. Invasive pulmonary aspergillosis in acute leukemia. The contribution of CT to early diagnosis and aggressive management. Chest 1987, 92. 95-9.
46. Caillot D., Casasnovas O., Bernard A., et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997, 15. 139-47.
47. Horger M., Hebart H., Einsele H., et al. Initial CT manifestations of invasive pulmonary aspergillosis in 45 non-HIV immunocompromised patients: association with patient outcome?. Eur J Radiol 2005, 55. 437-44.
48. Walsh T.J., Garrett K., Feurerstein E., et al. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob Agents Chemother 1995, 39. 1065-9.
49. Caillot D., Couaillier J.F., Bernard A., et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001, 19. 253-9.
50. von Eiff M., Roos N., Schulten R., et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995, 62. 341-7.
51. Walsh T.J., Hier D.B., Caplan L.R. Aspergillosis of the central nervous system: clinicopathological analysis of 17 patients. Ann Neurol 1985, 18. 574-82.
52. Walsh T.J., Hier D.B., Caplan L.R. Fungal infections of the central nervous system: comparative analysis of risk factors and clinical signs in 57 patients. Neurology 1985, 35. 1654-7.
53. Simpson M.B., Merz W.G., Kurlinski J.P., et al. Opportunistic mycotic osteomyelitis: bone infections due to Aspergillus and Candida species. Medicine (Baltimore) 1977, 56. 475-82.
54. McCarty J.M., Flam M.S., Pullen G., et al. Outbreak of primary cutaneous aspergillosis related to intravenous arm boards. J Pediatr 1986, 108. 721-4.
55. Prystowsky S.D., Vogelstein B., Ettinger D.S., et al. Invasive aspergillosis. N Engl J Med 1976, 295. 655-8.
56. Walsh T.J. Primary cutaneous aspergillosis-an emerging infection among immunocompromised patients. Clin Infect Dis 1998, 27. 453-7.
57. Binder R.E., Faling L.J., Pugatch R.D., et al. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine (Baltimore) 1982, 61. 109-24.
58. Saraceno J.L., Phelps D.T., Ferro T.J., et al. Chronic necrotizing pulmonary aspergillosis: approach to management. Chest 1997, 112. 541-8.
59. Berkow R.L., Weisman S.J., Provisor A.J., et al. Invasive aspergillosis of paranasal tissues in children with malignancies. J Pediatr 1983, 103:49-53.
60. Swerdlow B., Deresinski S. Development of Aspergillus sinusitis in a patient receiving amphotericin B. Treatment with granulocyte transfusions. Am J Med 1984, 76. 162-6.
61. Viollier A.F., Peterson D.E., De Jongh C.A., et al. Aspergillus sinusitis in cancer patients. Cancer 1986, 58. 366-71.
62. Torres H.A., Rivero G.A., Lewis R.E., et al. Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus. Diagn Microbiol Infect Dis 2003, 46. 25-8.
63. Hung C.C., Chang S.C., Yang P.C., et al. Invasive pulmonary pseudallescheriasis with direct invasion of the thoracic spine in an immunocompetent patient. Eur J Clin Microbiol Infect Dis 1994, 13. 749-51.
64. Yu V.L., Muder R.R., Poorsattar A. Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three-year prospective study. Am J Med 1986, 81. 249-54.
65. Treger T.R., Visscher D.W., Bartlett M.S., et al. Diagnosis of pulmonary infection caused by Aspergillus: usefulness of respiratory cultures. J Infect Dis 1985, 152. 572-6.
66. Kahn F.W., Jones J.M., England D.M. The role of bronchoalveolar lavage in the diagnosis of invasive pulmonary aspergillosis. Am J Clin Pathol 1986, 86. 518-23.
67. Saito H., Anaissie E.J., Morice R.C., et al. Bronchoalveolar lavage in the diagnosis of pulmonary infiltrates in patients with acute leukemia. Chest 1988, 94. 745-9.
68. Hope W.W., Walsh T.J., Denning D.W. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005, 5. 609-22.
69. Dupont B., Huber M., Kim S.J., et al. Galactomannan antigenemia and antigenuria in aspergillosis: studies in patients and experimentally infected rabbits. J Infect Dis 1987, 155:1-11.
70. Reiss E., Lehmann P.F. Galactomannan antigenemia in invasive aspergillosis. Infect Immun 1979, 25. 357-65.
71. Mennink-Kersten M.A., Donnelly J.P., Verweij P.E. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004, 4. 349-57.
72. Fortun J., Martin-Davila P., Alvarez M.E., et al. Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients. Transplantation 2001, 71. 145-9.
73. Husain S., Kwak E.J., Obman A., et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004, 4:796-802.
74. Kwak E.J., Husain S., Obman A., et al. Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol 2004, 42. 435-8.
75. Maertens J., Van Eldere J., Verhaegen J., et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002, 186. 1297-306.
76. Maertens J., Verhaegen J., Demuynck H., et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999, 37. 3223-8.
77. Verweij P.E., Weemaes C.M., Curfs J.H., et al. Failure to detect circulating Aspergillus markers in a patient with chronic granulomatous disease and invasive aspergillosis. J Clin Microbiol 2000, 38. 3900-1.
78. Becker M.J., Lugtenburg E.J., Cornelissen J.J., et al. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003, 121. 448-57.
79. Marr K.A., Balajee S.A., McLaughlin L., et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004, 190. 641-9.
80. Marr K.A., Laverdiere M., Gugel A., et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005, 40. 1762-9.
81. Herbrecht R., Letscher-Bru V., Oprea C., et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002, 20. 1898-906.
82. Maertens J., Theunissen K., Verbeken E., et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004, 126. 852-60.
83. Ulusakarya A., Chachaty E., Vantelon J.M., et al. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. Hematol J 2000, 1. 111-6.
84. Sulahian A., Touratier S., Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003, 349. 2366-7.
85. Viscoli C., Machetti M., Cappellano P., et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004, 38. 913-6.
86. Kontoyiannis D.P. Defining the diagnosis of invasive aspergillosis. Med Mycol 2006, 44:S163-S172.
87. El-Mahallawy H.A., Shaker H.H., Ali Helmy H., et al. Evaluation of pan-fungal PCR assay and Aspergillus antigen detection in the diagnosis of invasive fungal infections in high risk paediatric cancer patients. Med Mycol 2006, 44. 733-9.
88. Scotter J.M., Campbell P., Anderson T.P., et al. Comparison of PCR-ELISA and galactomannan detection for the diagnosis of invasive aspergillosis. Pathology 2005, 37. 246-53.
89. Bretagne S., Costa J.M., Bart-Delabesse E., et al. Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis. Clin Infect Dis 1988, 26. 1407-12.
90. Kami M., Fukui T., Ogawa S., et al. Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 2001, 33. 1504-12.
91. Kontoyiannis D.P., Bodey G.P. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 2002, 21. 161-72.
92. Francesconi A., Kasai M., Petraitiene R., et al. Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis. J Clin Microbiol 2006, 44. 2475-80.
93. Musher B., Fredricks D., Leisenring W., et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004, 42. 5517-22.
94. Pazos C., Ponton J., Del Palacio A. Contribution of (1,3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005, 43:299-305.
95. Kawazu M., Kanda Y., Nannya Y., et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1,3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004, 42. 2733-41.
96. Yuasa K., Goto H., Iguchi M., et al. Evaluation of the diagnostic value of the measurement of (1,3)-beta-D-glucan in patients with pulmonary aspergillosis. Respiration 1996, 63:78-83.
97. Rains B.M., Mineck C.W. Treatment of allergic fungal sinusitis with high-dose itraconazole. Am J Rhinol 2003, 17:1-8.
98. Chen J.C., Chang Y.L., Luh S.P., et al. Surgical treatment for pulmonary aspergilloma: a 28 year experience. Thorax 1997, 52. 810-3.
99. el Oakley R., Petrou M., Goldstraw P. Indications and outcome of surgery for pulmonary aspergilloma. Thorax 1997, 52. 813-5.
100. Aisner J., Wiernik P.H., Schimpff S.C. Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann Intern Med 1977, 86. 539-43.
101. Pennington J.E. Aspergillus pneumonia in hematologic malignancy. Improvements in diagnosis and therapy. Arch Intern Med 1977, 137. 769-71.
102. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347. 408-15.
103. Cornely O.A., Maertens J., Bresnik M., et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007, 44. 1289-97.
104. Walsh T.J., Anaissie E.J., Denning D.W., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46. 327-60.
105. Johnson M.D., MacDougall C., Ostrosky-Zeichner L., et al. Combination antifungal therapy. Antimicrob Agents Chemother 2004, 48:693-715.
106. Meletiadis J., Petraitis V., Petraitiene R., et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis 2006, 194. 1008-18.
107. Baron O., Guillaume B., Moreau P., et al. Aggressive surgical management in localized pulmonary mycotic and nonmycotic infections for neutropenic patients with acute leukemia: report of eighteen cases. J Thorac Cardiovasc Surg 1988, 115:63-83. discussion 68-9.
108. Robinson L.A., Reed E.C., Galbraith T.A., et al. Pulmonary resection for invasive Aspergillus infections in immunocompromised patients. J Thorac Cardiovasc Surg 1995, 109. 1182-96; discussion 1196-7, 1995.
109. Dixon D.M., Polak A., Walsh T.J. Fungus dose-dependent primary pulmonary aspergillosis in immunosuppressed mice. Infect Immun 1989, 57. 1452-6.
110. Francis P., Lee J.W., Hoffman A., et al. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J Infect Dis 1994, 169. 356-68.
111. Rhame F.S., Streifel A.J., Kersey J.H., et al. Extrinsic risk factors for pneumonia in the patient at high risk of infection. Am J Med 1984, 76:42-52.
112. Arnow P.M., Sadigh M., Costas C., et al. Endemic and epidemic aspergillosis associated with in-hospital replication of Aspergillus organisms. J Infect Dis 1991, 164:998-1002.
113. Anaissie E.J., Kuchar R.T., Rex J.H., et al. Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001, 33. 1871-8.
114. Anaissie E.J., Stratton S.L., Dignani M.C., et al. Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood 2003, 101. 2542-6.
115. De Pauw B.E. Practical modalities for prevention of fungal infections in cancer patients. Eur J Clin Microbiol Infect Dis 1997, 16:32-41.
116. Walsh T.J., De Pauw B., Anaissie E., et al. Recent advances in the epidemiology, prevention and treatment of invasive fungal infections in neutropenic patients. J Med Vet Mycol 1994, 32(suppl 1):33-51.
117. Walsh T.J., Lee J., Lecciones J., et al. Empiric therapy with amphotericin B in febrile granulocytopenic patients. Rev Infect Dis 1991, 13:496-503.
118. Vreugdenhil G., Van Dijke B.J., Donnelly J.P., et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 1993, 11. 353-8.
119. Robenshtok E., Gafter-Gvili A., Goldberg E., et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007, 25. 5471-89.
120. Cornely O.A., Maertens J., Winston D.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356. 348-59.
121. De Pauw B.E., Donnelly J.P. Prophylaxis and aspergillosis-has the principle been proven?. N Engl J Med 2007, 356. 409-11.
122. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356. 335-47.
123. Vehreschild J.J., Bohme A., Buchheidt D., et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007, 55. 445-9.
124. Cordonnier C., Maury S., Pautas C., et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004, 33. 943-8.
125. Bjerke J.W., Meyers J.D., Bowden R.A. Hepatosplenic candidiasis-a contraindication to marrow transplantation?. Blood 1994, 84. 2811-4.
126. Michailov G., Laporte J.P., Lesage S., et al. Autologous bone marrow transplantation is feasible in patients with a prior history of invasive pulmonary aspergillosis. Bone Marrow Transplant 1996, 17. 569-72.
127. Walsh T.J., Whitcomb P.O., Revankar S.G., et al. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995, 76. 2357-62.
128. Nemunaitis J., Meyers J.D., Buckner C.D., et al. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 1991, 78. 907-13.
129. Roilides E., Uhlig K., Venzon D., et al. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993, 61. 1185-93.
130. Dignani M.C., Anaissie E.J., Hester J.P., et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997, 11. 1621-30.
131. Stone R.M., Berg D.T., George S.L., et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995, 332. 1671-7.
132. Catalano L., Fontana R., Scarpato N., et al. Combined treatment with amphotericin-B and granulocyte transfusion from G-CSF-stimulated donors in an aplastic patient with invasive aspergillosis undergoing bone marrow transplantation. Haematologica 1997, 82. 71-2.
133. Roden M.M., Zaoutis T.E., Buchanan W.L., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41. 634-53.
134. Brown J.F., Gottlieb L.S., McCormick R.A. Pulmonary and rhinocerebral mucormycosis. Successful outcome with amphotericin B and griseofulvin therapy. Arch Intern Med 1977, 137. 936-8.
135. DeSouza R., MacKinnon S., Spagnolo S.V., et al. Treatment of localized pulmonary phycomycosis. South Med J 1979, 72. 609-12.
136. Hsu J., Clayman J.A., Geha A.S. Survival of a recipient of renal transplantation after pulmonary phycomycosis. Ann Thorac Surg 1989, 47. 617-9.
137. Kondoh Y., Shinada J., Hirai S., et al. (A case of pulmonary mucormycosis accompanied by lymphocytic leukemia successfully treated by pulmonary lobectomy). Nippon Kyobu Geka Gakkai Zasshi 1989, 37. 734-7.
138. Latif S., Saffarian N., Bellovich K., et al. Pulmonary mucormycosis in diabetic renal allograft recipients. Am J Kidney Dis 1997, 29. 461-4.
139. Meyer R.D., Armstrong D. Mucormycosis-changing status. CRC Crit Rev Clin Lab Sci 1973, 4. 421-51.
140. Meyer R.D., Rosen P., Armstrong D. Phycomycosis complicating leukemia and lymphoma. Ann Intern Med 1972, 77. 871-9.
141. Reed A.E., Body B.A., Austin M.B., et al. Cunninghamella bertholletiae and Pneumocystis carinii pneumonia as a fatal complication of chronic lymphocytic leukemia. Hum Pathol 1988, 19. 1470-2.
142. Rinaldi M.G. Zygomycosis. Infect Dis Clin North Am 1989, 3:19-41.
143. Studemeister A.E., Kozak K., Garrity E., et al. Survival of a heart transplant recipient after pulmonary cavitary mucormycosis. J Heart Transplant 1988, 7. 159-61.
144. Blatt S.P., Lucey D.R., DeHoff D., et al. Rhinocerebral zygomycosis in a patient with AIDS. J Infect Dis 1991, 164. 215-6.
145. Mostaza J.M., Barbado F.J., Fernandez-Martin J., et al. Cutaneoarticular mucormycosis due to Cunninghamella bertholletiae in a patient with AIDS. Rev Infect Dis 1989, 11. 316-8.
146. Smith A.G., Bustamante C.I., Gilmor G.D. Zygomycosis (absidiomycosis) in an AIDS patient. Absidiomycosis in AIDS. Mycopathologia 1989, 105:7-10.
147. Cohen M.S., Brook C.J., Naylor B., et al. Pulmonary phycomycetoma in a patient with diabetes mellitus. Am Rev Respir Dis 1977, 116. 519-23.
148. Johnson G.M., Baldwin J.J. Pulmonary mucormycosis and juvenile diabetes. Am J Dis Child 1981, 135. 567-8.
149. Yagihashi S., Watanabe K., Nagai K., et al. Pulmonary mucormycosis presenting as massive fatal hemoptysis in a hemodialytic patient with chronic renal failure. Klin Wochenschr 1991, 69. 224-7.
150. Lehrer RI H.D., Sypherd P.S. Mucormycosis (UCLA Conference). Ann Intern Med 1980, 93:93.
151. Marchevsky A.M., Bottone E.J., Geller S.A., et al. The changing spectrum of disease, etiology, and diagnosis of mucormycosis. Hum Pathol 1980, 11. 457-64.
152. Pagano L., Ricci P., Tonso A., et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto). Br J Haematol 1997, 99. 331-6.
153. Rex J.H., Ginsberg A.M., Fries L.F., et al. Cunninghamella bertholletiae infection associated with deferoxamine therapy. Rev Infect Dis 1988, 10. 1187-94.
154. Sugar A.M. Mucormycosis. Clin Infect Dis 1992, 14(suppl 1). S126-9.
155. Cohen-Abbo A., Bozeman P.M., Patrick C.C. Cunninghamella infections: review and report of two cases of Cunninghamella pneumonia in immunocompromised children. Clin Infect Dis 1993, 17. 173-7.
156. Dermoumi H. A rare zygomycosis due to Cunninghamella bertholletiae. Mycoses 1993, 36. 293-4.
157. Ng T.T., Campbell C.K., Rothera M., et al. Successful treatment of sinusitis caused by Cunninghamella bertholletiae. Clin Infect Dis 1994, 19. 313-6.
158. Walsh T.J., Renshaw G., Andrews J., et al. Invasive zygomycosis due to Conidiobolus incongruus. Clin Infect Dis 1994, 19. 423-30.
159. Waldorf A.R., Diamond R.D. Aspergillosis and mucormycosis. Immunology of the Fungal Diseases 1989, CRC Press, Boca Raton. R.A. Cox (Ed.).
160. Waldorf A.R., Halde C., Vedros N.A. Murine model of pulmonary mucormycosis in cortisone-treated mice. Sabouraudia 1982, 20. 217-24.
161. Waldorf A.R., Ruderman N., Diamond R.D. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest 1984, 74. 150-60.
162. Loevner L.A., Andrews J.C., Francis I.R. Multiple mycotic pulmonary artery aneurysms: a complication of invasive mucormycosis. Am J Roentgenol 1992, 158. 761-2.
163. Murray H.W. Pulmonary mucormycosis with massive fatal hemoptysis. Chest 1975, 68. 65-8.
164. Reich J., Renzetti A.D. Pulmonary phycomycosis. Report of a case of bronchocutaneous fistula formation and pulmonary arterial mycothrombosis. Am Rev Respir Dis 1970, 102. 959-64.
165. Carpenter D.F., Brubaker L.H., Powell R.D., Valsamis M.P. Phycomycotic thrombosis of the basilar artery. Neurology 1968, 18. 807-12.
166. Galetta S.L., Wulc A.E., Goldberg H.I., et al. Rhinocerebral mucormycosis: management and survival after carotid occlusion. Ann Neurol 1990, 28. 103-7.
167. Kramer B.S., Hernandez A.D., Reddick R.L., et al. Cutaneous infarction. Manifestation of disseminated mucormycosis. Arch Dermatol 1977, 113. 1075-6.
168. Lowe J.T., Hudson W.R. Rhincerebral phycomycosis and internal carotid artery thrombosis. Arch Otolaryngol 1975, 101. 100-3.
169. Luo Q.L., Orcutt J.C., Seifter L.S. Orbital mucormycosis with retinal and ciliary artery occlusions. Br J Ophthalmol 1989, 73. 680-3.
170. Smith J.L., Stevens D.A. Survival in cerebro-rhino-orbital zygomycosis and cavernous sinus thrombosis with combined therapy. South Med J 1986, 79. 501-4.
171. Van Johnson E., Kline L.B., Julian B.A., et al. Bilateral cavernous sinus thrombosis due to mucormycosis. Arch Ophthalmol 1988, 106. 1089-92.
172. Abramson E., Wilson D., Arky R.A. Rhinocerebral phycomycosis in association with diabetic ketoacidosis. Report of two cases and a review of clinical and experimental experience with amphotericin B therapy. Ann Intern Med 1967, 66. 735-42.
173. Artis W.M., Fountain J.A., Delcher H.K., et al. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982, 31. 1109-14.
174. Artis W.M., Patrusky E., Rastinejad F., et al. Fungistatic mechanism of human transferrin for Rhizopus oryzae and Trichophyton mentagrophytes: alternative to simple iron deprivation. Infect Immun 1983, 41. 1269-78.
175. Chinn R.Y., Diamond R.D. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun 1982, 38. 1123-9.
176. Diamond R.D., Clark R.A. Damage to Aspergillus fumigatus and Rhizopus oryzae hyphae by oxidative and nonoxidative microbicidal products of human neutrophils in vitro. Infect Immun 1982, 38. 487-95.
177. Eng R.H., Corrado M., Chin E. Susceptibility of Zygomycetes to human serum. Sabouraudia 1981, 19. 111-5.
178. Jones H.E. Serum transferrins, pH linked to resistance in KDA patients. Dermatol Obser 1979, 2.
179. Sheldon W.H., Bauer H. The development of the acute inflammatory response to experimental cutaneous mucormycosis in normal and diabetic rabbits. J Exp Med 1959, 110. 845-52.
180. Abe F., Inaba H., Katoh T., et al. Effects of iron and desferrioxamine on Rhizopus infection. Mycopathologia 1990, 110. 87-91.
181. Arimura Y., Nakabayashi K., Kitamoto K., et al. (Mucormycosis in a hemodialysis patient with iron overload). Nippon Naika Gakkai Zasshi 1988, 77. 1884-7.
182. Boelaert J.R., de Locht M., Schneider Y.J. The effect of deferoxamine on different zygomycetes. J Infect Dis 1994, 169. 231-2.
183. Boelaert J.R., de Locht M., Van Cutsem J., et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993, 91. 1979-86.
184. Boelaert J.R., Fenves A.Z., Coburn J.W. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991, 18. 660-7.
185. Boelaert J.R., van Roost G.F., Vergauwe P.L., et al. The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature. Clin Nephrol 1988, 29. 261-6.
186. Daly A.L., Velazquez L.A., Bradley S.F., et al. Mucormycosis: association with deferoxamine therapy. Am J Med 1989, 87. 468-71.
187. Kolbeck P.C., Makhoul R.G., Bollinger R.R., et al. Widely disseminated Cunninghamella mucormycosis in an adult renal transplant patient: case report and review of the literature. Am J Clin Pathol 1985, 83. 747-53.
188. Nakamura M., Weil W.B., Kaufman D.B. Fatal fungal peritonitis in an adolescent on continuous ambulatory peritoneal dialysis: association with deferoxamine. Pediatr Nephrol 1989, 3. 80-2.
189. Ponz E., Campistol J.M., Ribalta T., et al. (Disseminated mucormycosis in a hemodialyzed female patient treated with deferoxamine). Rev Clin Esp 1991, 188. 85-7.
190. Slade M.P., McNab A.A. Fatal mucormycosis therapy associated with deferoxamine. Am J Ophthalmol 1991, 112. 594-5.
191. Vandevelde L., Bondewel C., Dubois M., et al. Mucorales and deferoxamine: from saprophytic to pathogenic state. Acta Otorhinolaryngol Belg 1990, 44. 429-33.
192. Eisenberg L., Wood T., Boles R. Mucormycosis. Laryngoscope 1977, 87. 347-56.
193. Ferry A.P. Cerebral mucormycosis (phycomycosis), Ocular findings and review of literatue. Surv Ophthalmol 1961, 6:1-24.
194. Straatsma B.R., Zimmerman L.E., Gass J.D. Phycomycosis. A clinicopathologic study of fifty-one cases. Lab Invest 1962, 11. 963-85.
195. Humphry R.C., Wright G., Rich W.J., et al. Acute proptosis and blindness in a patient with orbital phycomycosis. J R Soc Med 1989, 82. 304-5.
196. Hyatt D.S., Young Y.M., Haynes K.A., et al. Rhinocerebral mucormycosis following bone marrow transplantation. J Infect 1992, 24:67-71.
197. Bruck H.M., Nash G., Foley D., et al. Opportunistic fungal infection of the burn wound with phycomycetes and Aspergillus. A clinical-pathologic review. Arch Surg 1971, 102. 476-82.
198. Abedi E., Sismanis A., Choi K., et al. Twenty-five years' experience treating cerebro-rhino-orbital mucormycosis. Laryngoscope 1984, 94. 1060-2.
199. Finn D.G. Mucormycosis of the paranasal sinuses. Ear Nose Throat J 1988, 67. 813, 846-8; 821-2.
200. Greenberg M.R., Lippman S.M., Grinnell V.S., et al. Computed tomographic findings in orbital Mucor. West J Med 1985, 143. 102-3.
201. Kline M.W. Mucormycosis in children: review of the literature and report of cases. Pediatr Infect Dis 1985, 4. 672-6.
202. Lazo A., Wilner H.I., Metes J.J. Craniofacial mucormycosis: computed tomographic and angiographic findings in two cases. Radiology 1981, 139. 623-6.
203. Parfrey N.A. Improved diagnosis and prognosis of mucormycosis. A clinicopathologic study of 33 cases. Medicine (Baltimore) 1986, 65. 113-23.
204. Price D.L., Wolpow E.R., Richardson E.P. Intracranial phycomycosis: a clinicopathological and radiological study. J Neurol Sci 1971, 14. 359-75.
205. Yousem D.M., Galetta S.L., Gusnard D.A., et al. MR findings in rhinocerebral mucormycosis. J Comput Assist Tomogr 1989, 13. 878-82.
206. McBride P.A., Dammin G.H. Mucormycosis: two cases of disseminated disease with cultural identification of Rhizopus. Review of the literature. Am J Med 1960, 28:832.
207. Jamadar D.A., Kazerooni E.A., Daly B.D., et al. Pulmonary zygomycosis: CT appearance. J Comput Assist Tomogr 1995, 19. 733-8.
208. McAdams H.P., Rosado de Christenson M., Strollo D.C., et al. Pulmonary mucormycosis: radiologic findings in 32 cases. Am J Roentgenol 1997, 168. 1541-8.
209. Watts W.J. Bronchopleural fistula followed by massive fatal hemoptysis in a patient with pulmonary mucormycosis. A case report. Arch Intern Med 1983, 143. 1029-30.
210. Pagano L., Ricci P., Nosari A., et al. Fatal haemoptysis in pulmonary filamentous mycosis: an underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature. Gimema Infection Program (Gruppo Italiano Malattie Ematologiche dell'Adulto). Br J Haematol 1995, 89. 500-05.
211. Bartrum R.J., Watnick M., Herman P.G. Roentgenographic findings in pulmonary mucormycosis. Am J Roentgenol Radium Ther Nucl Med 1973, 117. 810-5.
212. Collins D.M., Dillard T.A., Grathwohl K.W., et al. Bronchial mucormycosis with progressive air trapping. Mayo Clin Proc 1999, 74:698-701.
213. Fermanis G.G., Matar K.S., Steele R. Endobronchial zygomycosis. Aust NZ J Surg 1991, 61. 391-3.
214. Leong A.S. Granulomatous mediastinitis due to rhizopus species. Am J Clin Pathol 1978, 70. 103-7.
215. Rothstein R.D., Simon G.L. Subacute pulmonary mucormycosis. J Med Vet Mycol 1986, 24. 391-4.
216. Chapman R.S., Kaplan W., Ajello L., et al. Color Atlas and Text of the Histopathology of Mycotic Diseases 1999, Mosby-Year Book, Chicago.
217. Mamlok V., Cowan W.T., Schnadig V. Unusual histopathology of mucormycosis in acute myelogenous leukemia. Am J Clin Pathol 1987, 88. 117-20.
218. Prokopowicz G.P., Bradley S.F., Kauffman C.A. Indolent zygomycosis associated with deferoxamine chelation therapy. Mycoses 1994, 37. 427-31.
219. Agger W.A., Maki D.G. Mucormycosis. A complication of critical care. Arch Intern Med 1978, 138. 925-7.
220. Cocanour C.S., Miller-Crotchett P., Reed R.L., Johnson P.C., Fischer R.P. Mucormycosis in trauma patients. J Trauma 1992, 32. 12-5.
221. Rozich J., Oxendine D., Heffner J., et al. Pulmonary zygomycosis. A cause of positive lung scan diagnosed by bronchoalveolar lavage. Chest 1989, 95. 238-40.
222. Chandler F.W., Watts J.C., Kaplan W., et al. Zygomycosis. Report of four cases with formation of chlamydoconidia in tissue. Am J Clin Pathol 1985, 84:99-103.
223. Goodman N.L. Agents of zygomycosis. Manual of Clinical Microbiology 1991, American Society for Microbiology, Washington DC, 674-92. 5th edn. A. Balows (Ed.).
224. Berger C.J., Disque F.C., Topazian R.G. Rhinocerebral mucormycosis: diagnosis and treatment. Report of two cases. Oral Surg Oral Med Oral Pathol 1975, 40:27-33.
225. Breiman A., Sadowsky D., Friedman J. Mucormycosis. Discussion and report of a case involving the maxillary sinus. Oral Surg Oral Med Oral Pathol 1981, 52. 375-8.
226. Ferstenfeld J.E., Cohen S.H., Rose H.D., et al. Chronic rhinocerebral phycomycosis in association with diabetes. Postgrad Med J 1977, 53. 337-42.
227. Hamill R., Oney L.A., Crane L.R. Successful therapy for rhinocerebral mucormycosis with associated bilateral brain abscesses. Arch Intern Med 1983, 143. 581-3.
228. Rakover Y., Vered I., Garzuzi H., et al. Rhinocerebral phycomycosis; combined approach therapy: case report. J Laryngol Otol 1985, 99. 1279-80.
229. Rosenberger R.S., West B.C., King J.W. Survival from sino-orbital mucormycosis due to Rhizopus rhizopodiformis. Am J Med Sci 1983, 286:25-30.
230. Kohn R., Hepler R. Management of limited rhino-orbital mucormycosis without exenteration. Ophthalmology 1985, 92. 1440-4.
231. Levy S.A., Schmitt K.W., Kaufman L. Systemic zygomycosis diagnosed by fine needle aspiration and confirmed with enzyme immunoassay. Chest 1986, 90. 146-8.
232. West B.C., Kwon-Chung K.J., King J.W., et al. Inguinal abscess caused by Rhizopus rhizopodiformis: successful treatment with surgery and amphotericin B. J Clin Microbiol 1983, 18. 1384-7.
233. Tedder M., Spratt J.A., Anstadt M.P., et al. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994, 57. 1044-50.
234. Chayakulkeeree M., Ghannoum M.A., Perfect J.R. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006, 25. 215-29.
235. Crompton J.A., Alexander D., Somerville T., et al. Lipid-based amphotericin in pulmonary zygomycosis: safety and efficacy of high exposure in a renal allograft recipient. Transpl Infect Dis 2004, 6. 183-7.
236. Herbrecht R., Letscher-Bru V., Bowden R.A., et al. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 2001, 20. 460-6.
237. Kofteridis D.P., Karabekios S., Panagiotides J.G., et al. Successful treatment of rhinocerebral mucormycosis with liposomal amphotericin B and surgery in two diabetic patients with renal dysfunction. J Chemother 2003, 15. 282-6.
238. Walsh T.J., Hiemenz J.W., Seibel N.L., et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998, 26. 1383-96.
239. Walsh TJ. Advances in the Management of Zygomycosis from Bench to Bedside: Treating a Recalcitrant Pathogen. Draft 2008.
240. Imhof A., Balajee S.A., Fredricks D.N., et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004, 39. 743-6.
241. Kobayashi K., Kami M., Murashige N., et al. Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis. Haematologica 2004, 89:ECR42.
242. Kontoyiannis D.P., Lionakis M.S., Lewis R.E., et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191. 1350-60.
243. Marty F.M., Cosimi L.A., Baden L.R. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004, 350. 950-2.
244. Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 2005, 40. 770-1.
245. Siwek G.T., Dodgson K.J., de Magalhaes-Silverman M., et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004, 39. 584-7.
246. Trifilio S.M., Bennett C.L., Yarnold P.R., et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007, 39. 425-9.
247. Petrikkos G., Skiada A. Recent advances in antifungal chemotherapy. Int J Antimicrob Agents 2007, 30. 108-17.
248. van Burik J.A., Hare R.S., Solomon H.F., et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006, 42. e61-e5.
249. Del Poeta M., Schell W.A., Perfect J.R. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother 1997, 41. 1835-6.
250. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998, 36. 2950-6.
251. Perlroth J., Choi B., Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007, 45. 321-46.
252. Ibrahim A.S., Bowman J.C., Avanessian V., et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005, 49. 721-7.
253. Spellberg B., Fu Y., Edwards J.E., et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005, 49. 830-2.
254. Reed C BR, Ibrahim AS, Edwards J, et al. Combination polyene-caspofungin in treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis.
255. Boelaert J.R., Van Cutsem J., de Locht M., et al. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int 1994, 45. 667-71.
256. Ibrahim A.S., Edwards J.E., Fu Y., et al. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 2006, 58. 1070-3.
257. Reed C., Ibrahim A., Edwards J.E., et al. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006, 50. 3968-9.
258. Ferguson B.J., Mitchell T.G., Moon R., et al. Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. Rev Infect Dis 1988, 10. 551-9.
259. Couch L., Theilen F., Mader J.T. Rhinocerebral mucormycosis with cerebral extension successfully treated with adjunctive hyperbaric oxygen therapy. Arch Otolaryngol Head Neck Surg 1988, 114. 791-4.
260. Melero M., Kaimen Maciel I., Tiraboschi N., et al. (Adjunctive treatment with hyperbaric oxygen in a patient with rhino-sinuso-orbital mucormycosis). Medicina (B Aires) 1991, 51. 53-5.
261. Yohai R.A., Bullock J.D., Aziz A.A., et al. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 1994, 39:3-22.
262. Martino P., Gastaldi R., Raccah R., et al. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect 1994, 28(suppl 1):7-15.
263. Anaissie E., Bodey G.P., Kantarjian H., et al. New spectrum of fungal infections in patients with cancer. Rev Infect Dis 1989, 11. 369-78.
264. Anaissie E., Kantarjian H., Jones P., et al. Fusarium. A newly recognized fungal pathogen in immunosuppressed patients. Cancer 1986, 57. 2141-5.
265. Boutati E.I., Anaissie E.J. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997, 90:999-1008.
266. Merz W.G., Karp J.E., Hoagland M., et al. Diagnosis and successful treatment of fusariosis in the compromised host. J Infect Dis 1988, 158. 1046-55.
267. Nucci M., Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002, 35. 909-20.
268. Perfect J.R., Marr K.A., Walsh T.J., et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003, 36. 1122-31.
269. Raad I.I., Hachem R.Y., Herbrecht R., et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006, 42. 1398-403.
270. Arikan S., Lozano-Chiu M., Paetznick V., et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002, 46. 245-7.
271. Fatoye ABE, Loewen R. Amphotericin B lipid complex and caspofungin as combination therapy for disseminated fusariosis in a patient with acute myeloid leukemia. Paper presented at the 13th Congress of the International Society for Human and Animal Mycology, San Antonio, Texas, 2003.
272. Vagace J.M., Sanz-Rodriguez C., Casado M.S., et al. Resolution of disseminated fusariosis in a child with acute leukemia treated with combined antifungal therapy: a case report. BMC Infect Dis 2007, 7:40.
273. Cuenca-Estrella M., Ruiz-Diez B., Martinez-Suarez J.V., et al. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 1999, 43. 149-51.
274. Meletiadis J., Meis J.F., Mouton J.W., et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002, 46. 62-8.
275. Zeng J., Kamei K., Zheng Y., et al. Susceptibility of Pseudallescheria boydii and Scedosporium apiospermum to new antifungal agents. Nippon Ishinkin Gakkai Zasshi 2004, 45. 101-4.
276. Jabado N., Casanova J.L., Haddad E., et al. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin Infect Dis 1998, 27. 1437-41.
277. Gonzalez G.M., Tijerina R., Najvar L.K., et al. Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays. Antimicrob Agents Chemother 2003, 47. 1436-8.
278. Minassian B., Huczko E., Washo T., et al. In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates. Clin Microbiol Infect 2003, 9. 1250-2.
279. O'Bryan T.A. Pseudallescheriasis in the 21st century. Expert Rev Anti Infect Ther 2005, 3. 765-73.
280. Pfaller M.A., Marco F., Messer S.A., et al. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998, 30. 251-5.
281. Ortoneda M., Pastor F.J., Mayayo E., et al. Comparison of the virulence of Scedosporium prolificans strains from different origins in a murine model. J Med Microbiol 2002, 51. 924-8.
282. Cortez KJ ea. In: IDSA. Guidelines San Diego, 2007.
283. Cortez K.J., Quiroz-Telles F., Meletiadis J., et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008, 21(1). 157-97.
284. Fredricks D.N., Rojanasthien N., Jacobson M.A. AIDS-related disseminated histoplasmosis in San Francisco, California. West J Med 1997, 167. 315-21.
285. Davies S.F. Diagnosis of pulmonary fungal infections. Semin Respir Infect 1988, 3. 162-71.
286. Moscardi-Bacchi M., Soares A., Mendes R., et al. In situ localization of T lymphocyte subsets in human paracoccidioidomycosis. J Med Vet Mycol 1989, 27. 149-58.
287. Schwarz J. Histoplasmosis 1981, Plenum Press, New York.
288. Singer-Vermes L.M., Burger E., Franco M.F., et al. Evaluation of the pathogenicity and immunogenicity of seven Paracoccidioides brasiliensis isolates in susceptible inbred mice. J Med Vet Mycol 1989, 27:71-82.
289. de Monbreun W.A. The cultivation and cultural characteristics of Darling's Histoplasma capsulatum. Am J Trop Med Hyg 1934, 14:93-135.
290. Graham A.R., Sobonya R.E., Bronnimann D.A., et al. Quantitative pathology of coccidioidomycosis in acquired immunodeficiency syndrome. Hum Pathol 1988, 19. 800-6.
291. Drouhet E. African histoplasmosis. Tropical Fungal Infections. Baillière's Clinical Tropical Medicine and Communicable Diseases 1989, vol. 4:221-247. International Practice and Research, Baillière Tindall, Philadelphia. R.J. Hay (Ed.).
292. Galgiani J.N. Coccidioidomycosis. Curr Clin Top Infect Dis 1997, 17:188-204.
293. Segal G.P. Serodiagnostic procedures in the systemic mycoses. Semin Resp Med 1987, 9. 136-44.
294. Wheat J., Sarosi G., McKinsey D., et al. Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America. Clin Infect Dis 2000, 30. 688-95.
295. Wheat L.J., Freifeld A.G., Kleiman M.B., et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007, 45. 807-25.
296. Goodwin R.A., Loyd J.E., Des Prez R.M. Histoplasmosis in normal hosts. Medicine (Baltimore) 1981, 60. 231-66.
297. Wheat L.J. Diagnosis and management of histoplasmosis. Eur J Clin Microbiol Infect Dis 1989, 8. 480-90.
298. Wheat L.J., Batteiger B.E., Sathapatayavongs B. Histoplasma capsulatum infections of the central nervous system. A clinical review. Medicine (Baltimore) 1990, 69. 244-60.
299. Kaufman L. Immunohistologic diagnosis of systemic mycoses: an update. Eur J Epidemiol 1992, 8. 377-82.
300. Wheat L.J. Systemic fungal infections: diagnosis and treatment. I. Histoplasmosis. Infect Dis Clin North Am 1988, 2. 841-59.
301. Graybill J.R. Histoplasmosis and AIDS. J Infect Dis 1988, 158. 623-6.
302. Minamoto G., Armstrong D. Fungal infections in AIDS. Histoplasmosis and coccidioidomycosis. Infect Dis Clin North Am 1988, 2. 447-56.
303. Wheat L.J., Connolly-Stringfield P.A., Baker R.L., et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990, 69. 361-74.
304. Wheat L.J., Slama T.G., Norton J.A., et al. Risk factors for disseminated or fatal histoplasmosis. Analysis of a large urban outbreak. Ann Intern Med 1982, 96. 159-63.
305. Conces D.J., Stockberger S.M., Tarver R.D., et al. Disseminated histoplasmosis in AIDS: findings on chest radiographs. Am J Roentgenol 1993, 160. 15-9.
306. Wheat L.J., Kohler R.B., Tewari R.P. Diagnosis of disseminated histoplasmosis by detection of Histoplasma capsulatum antigen in serum and urine specimens. N Engl J Med 1986, 314. 83-8.
307. Williams B., Fojtasek M., Connolly-Stringfield P., et al. Diagnosis of histoplasmosis by antigen detection during an outbreak in Indianapolis, Ind. Arch Pathol Lab Med 1994, 118. 1205-8.
308. Kauffman C.A. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev 2007, 20. 115-32.
309. Johnson P.C., Wheat L.J., Cloud G.A., et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002, 137. 105-9.
310. Durkin M.M., Connolly P.A., Wheat L.J. Comparison of radioimmunoassay and enzyme-linked immunoassay methods for detection of Histoplasma capsulatum var. capsulatum antigen. J Clin Microbiol 1997, 35. 2252-5.
311. Durry E., Pappagianis D., Werner S.B., et al. Coccidioidomycosis in Tulare County, California, 1991: reemergence of an endemic disease. J Med Vet Mycol 1997, 35. 321-6.
312. Einstein H.E., Johnson R.H. Coccidioidomycosis: new aspects of epidemiology and therapy. Clin Infect Dis 1993, 16. 349-54.
313. Fisher MC K.G., White T.J., Taylor J.W. Molecular and phenotypic description of Coccidioides posadasii sp. nov., previously recognized as the non-California population of Coccidioides immitis. Mycologia 2002, 94:73-84.
314. Ampel N.M. Combating opportunistic infections: coccidioidomycosis. Expert Opin Pharmacother 2004, 5. 255-61.
315. Bronnimann D.A., Galgiani J.N. Coccidioidomycosis. Eur J Clin Microbiol Infect Dis 1989, 8. 466-73.
316. Galgiani J.N., Ampel N.M. Coccidioides immitis in patients with human immunodeficiency virus infections. Semin Respir Infect 1990, 5. 151-4.
317. Knoper S.R., Galgiani J.N. Systemic fungal infections: diagnosis and treatment. I. Coccidioidomycosis. Infect Dis Clin North Am 1988, 2. 861-75.
318. Bergstrom L., Yocum D.E., Ampel N.M., et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 2004, 50. 1959-66.
319. DiTomasso J.P., Ampel N.M., Sobonya R.E., et al. Bronchoscopic diagnosis of pulmonary coccidioidomycosis. Comparison of cytology, culture, and transbronchial biopsy. Diagn Microbiol Infect Dis 1994, 18. 83-7.
320. Raab S.S., Silverman J.F., Zimmerman K.G. Fine-needle aspiration biopsy of pulmonary coccidiodomycosis. Spectrum of cytologic findings in 73 patients. Am J Clin Pathol 1993, 99. 582-7.
321. Coccidioidomycosis. A text 1980, Plenum Press, New York. D.A. Stevens (Ed.).
322. Chiller T.M., Galgiani J.N., Stevens D.A. Coccidioidomycosis. Infect Dis Clin North Am 2003, 17:41-57. viii.
323. Pappagianis D. Epidemiology of coccidioidomycosis. Curr Top Med Mycol 1988, 2:199-238.
324. Dolan M.J., Lattuada C.P., Melcher G.P., et al. Coccidioides immitis presenting as a mycelial pathogen with empyema and hydropneumothorax. J Med Vet Mycol 1992, 30. 249-55.
325. Beard J.S., Benson P.M., Skillman L. Rapid diagnosis of coccidioidomycosis with a DNA probe to ribosomal RNA. Arch Dermatol 1993, 129. 1589-93.
326. Galgiani J.N., Catanzaro A., Cloud G.A., et al. Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group. Ann Intern Med 1993, 119:28-35.
327. Galgiani J.N., Stevens D.A., Graybill J.R., et al. Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400-and 800-mg doses and observations at higher doses. Am J Med 1988, 84. 603-10.
328. Tucker R.M., Williams P.L., Arathoon E.G., et al. Treatment of mycoses with itraconazole. Ann NY Acad Sci 1988, 544. 451-70.
329. Graybill J.R. Treatment of coccidioidomycosis. Curr Top Med Mycol 1993, 5. 151-79.
330. Oldfield E.C., Bone W.D., Martin C.R., et al. Prediction of relapse after treatment of coccidioidomycosis. Clin Infect Dis 1997, 25. 1205-10.
331. Catanzaro A., Galgiani J.N., Levine B.E., et al. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group. Am J Med 1995, 98. 249-56.
332. Galgiani J.N., Catanzaro A., Cloud G.A., et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med 2000, 133. 676-86.
333. Gonzalez G.M., Tijerina R., Najvar L.K., et al. Efficacies of amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposomal AMB, and conventional AMB in treatment of murine coccidioidomycosis. Antimicrob Agents Chemother 2004, 48. 2140-3.
334. Cortez K.J., Walsh T.J., Bennett J.E. Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis 2003, 36. 1619-22.
335. Catanzaro A., Cloud G.A., Stevens D.A., et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis 2007, 45. 562-8.
336. Bradsher R.W. A clinician's view of blastomycosis. Curr Top Med Mycol 1993, 5:181-200.
337. Bradsher R.W. Clinical features of blastomycosis. Semin Respir Infect 1997, 12. 229-34.
338. Kuzo R.S., Goodman L.R. Blastomycosis. Semin Roentgenol 1996, 31:45-51.
339. Meyer K.C., McManus E.J., Maki D.G. Overwhelming pulmonary blastomycosis associated with the adult respiratory distress syndrome. N Engl J Med 1993, 329. 1231-6.
340. Mitchell T.G. Blastomycosis. Textbook of Pediatric Infectious Diseases 1988, WB Saunders, Philadelphia, 1927-38. R. Feigin, J.D. Cherry (Eds.).
341. Sanders J.S., Sarosi G.A., Nollet D.J., Thompson J.I. Exfoliative cytology in the rapid diagnosis of pulmonary blastomycosis. Chest 1977, 72. 193-6.
342. Steck W.D. Blastomycosis. Dermatol Clin 1989, 7:241-250.
343. Kravitz G.R., Davies S.F., Eckman M.R., et al. Chronic blastomycotic meningitis. Am J Med 1981, 71. 501-5.
344. Dismukes W.E., Bradsher R.W., Cloud G.C., et al. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med 1992, 93. 489-97.
345. Panicker J., Walsh T., Kamani N. Recurrent central nervous system blastomycosis in an immunocompetent child treated successfully with sequential liposomal amphotericin B and voriconazole. Pediatr Infect Dis J 2006, 25. 377-9.
346. Yamada H., Kotaki H., Takahashi T. Recommendations for the treatment of fungal pneumonias. Expert Opin Pharmacother 2003, 4. 1241-58.
347. USPHS/IDSA Prevention of Opportunistic Infections Working Group 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. US Public Health Services/Infectious Diseases Society of America. Clin Infect Dis 1997, 25(suppl 3). S313-35.
348. Sugar A.M., Liu X.P. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 1996, 40. 1314-6.
349. Clemons K.V., Stevens D.A. Efficacy of nikkomycin Z against experimental pulmonary blastomycosis. Antimicrob Agents Chemother 1997, 41. 2026-8.
350. Brummer E., Castaneda E., Restrepo A. Paracoccidioidomycosis: an update. Clin Microbiol Rev 1993, 6:89-117.
351. Restrepo A. The ecology of Paracoccidioides brasiliensis: a puzzle still unsolved. Sabouraudia 1985, 23. 323-34.
352. Cano L.E., Kashino S.S., Arruda C., et al. Protective role of gamma interferon in experimental pulmonary paracoccidioidomycosis. Infect Immun 1998, 66. 800-6.
353. Restrepo A., Salazar M.E., Cano L.E., et al. Estrogens inhibit mycelium-to-yeast transformation in the fungus Paracoccidioides brasiliensis: implications for resistance of females to paracoccidioidomycosis. Infect Immun 1984, 46. 346-53.
354. Shikanai-Yasuda M.A., Assis C.M., Takeda K.M., et al. Monocyte adherence to Paracoccidioides brasiliensis, zymosan-C3b and erythrocyte-hemolysin in patients with paracoccidioidomycosis. Mycopathologia 1997, 138. 65-9.
355. Rippon J.W. The pathogenic fungi and the pathogenic actinomycetes. Medical Mycology 1988, WB Saunders, Philadelphia. 3rd edn.
356. Sugar A.M. Systemic fungal infections: diagnosis and treatment. I. Paracoccidioidomycosis. Infect Dis Clin North Am 1988, 2. 913-24.
357. Supparatpinyo K., Khamwan C., Baosoung V., et al. Disseminated Penicillium marneffei infection in southeast Asia. Lancet 1994, 344. 110-3.
358. Supparatpinyo K., Perriens J., Nelson K.E., et al. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med 1988, 339. 1739-43.
359. Marty F., Mylonakis E. Antifungal use in HIV infection. Expert Opin Pharmacother 2002, 3:91-102.
360. Sirisanthana T., Supparatpinyo K., Perriens J., et al. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin Infect Dis 1998, 26. 1107-10.
361. Supparatpinyo K., Chiewchanvit S., Hirunsri P., et al. An efficacy study of itraconazole in the treatment of Penicillium marneffei infection. J Med Assoc Thai 1992, 75. 688-91.
362. Chaiwarith R., Charoenyos N., Sirisanthana T., et al. Discontinuation of secondary prophylaxis against penicilliosis marneffei in AIDS patients after HAART. AIDS 2007, 21. 365-7.
363. Chariyalertsak S., Supparatpinyo K., Sirisanthana T., et al. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002, 34. 277-84.
364. Pluss J.L., Opal S.M. Pulmonary sporotrichosis: review of treatment and outcome. Medicine (Baltimore) 1986, 65. 143-53.
365. Pueringer R.J., Iber C., Deike M.A., et al. Spontaneous remission of extensive pulmonary sporotrichosis. Ann Intern Med 1986, 104. 366-7.
366. Kauffman C.A., Hajjeh R., Chapman S.W., Mycoses Study Group Practice guidelines for the management of patients with sporotrichosis. Infectious Diseases Society of America. Clin Infect Dis 2000, 30. 684-7.
367. Chang W.C., Tzao C., Hsu H.H., et al. Pulmonary cryptococcosis: comparison of clinical and radiographic characteristics in immunocompetent and immunocompromised patients. Chest 2006, 129. 333-40.
368. Lam C.L., Lam W.K., Wong Y., et al. Pulmonary cryptococcosis: a case report and review of the Asian-Pacific experience. Respirology 2001, 6. 351-5.
369. Shibuya K., Hirata A., Omuta J., et al. Granuloma and cryptococcosis. J Infect Chemother 2005, 11. 115-22.
370. Allende M., Pizzo P.A., Horowitz M., et al. Pulmonary cryptococcosis presenting as metastases in children with sarcomas. Pediatr Infect Dis J 1993, 12. 240-3.
371. Newman T.G., Soni A., Acaron S., et al. Pleural cryptococcosis in the acquired immune deficiency syndrome. Chest 1987, 91. 459-61.
372. Suffredini A.F., Ognibene F.P., Lack E.E., et al. Non-specific interstitial pneumonitis: a common cause of pulmonary disease in the acquired immunodeficiency syndrome. Ann Intern Med 1987, 107:7-13.
373. Wasser L., Talavera W. Pulmonary cryptococcosis in AIDS. Chest 1987, 92. 692-5.
374. Powderly W.G., Cloud G.A., Dismukes W.E., et al. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1994, 18. 789-92.
375. Lortholary O., Nunez H., Brauner M.W., et al. Pulmonary cryptococcosis. Semin Respir Crit Care Med 2004, 25. 145-57.
376. Perfect J.R., Casadevall A. Cryptococcosis. Infect Dis Clin North Am 2002, 16. 837-74, v-vi.
377. Powderly W.G., Saag M.S., Cloud G.A., et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med 1992, 326. 793-8.
378. Sharkey P.K., Graybill J.R., Johnson E.S., et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996, 22. 315-21.
379. Coker R.J., Viviani M., Gazzard B.G., et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 1993, 7. 829-35.
380. Joly V., Aubry P., Ndayiragide A., et al. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1996, 23. 556-62.
381. Haron E., Vartivarian S., Anaissie E., et al. Primary Candida pneumonia. Experience at a large cancer center and review of the literature. Medicine (Baltimore) 1993, 72. 137-42.
382. Masur H., Rosen P.P., Armstrong D. Pulmonary disease caused by Candida species. Am J Med 1977, 63. 914-25.
383. Walsh T.J., Melcher G.P., Lee J.W., et al. Infections due to Trichosporon species: new concepts in mycology, pathogenesis, diagnosis and treatment. Curr Top Med Mycol 1993, 5:79-113.
384. Edman J.C., Kovacs J.A., Masur H., et al. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988, 334. 519-22.
385. Wazir J.F., Ansari N.A. Pneumocystis carinii infection. Update and review. Arch Pathol Lab Med 2004, 128. 1023-7.
386. Durand-Joly I., Chabe M., Soula F., et al. Molecular diagnosis of Pneumocystis pneumonia. FEMS Immunol Med Microbiol 2005, 45. 405-10.
387. Deresinski S.C. Treatment of Pneumocystis carinii pneumonia in adults with AIDS. Semin Respir Infect 1977, 12:79-97.
388. Korraa H., Saadeh C. Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole. South Med J 1996, 89. 272-7.
389. Briel M., Bucher H.C., Boscacci R., et al. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database Syst Rev 2006, 3. CD006150.
390. Pareja J.G., Garland R., Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998, 113. 1215-24.
391. Shankar S.M., Nania J.J. Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy. Paediatr Drugs 2007, 9. 301-9.